During a recent earnings call, Hims & Hers Health CEO Andrew Dudum confirmed that the company is expanding its product offerings to include compounded peptides. These products are being developed for the U.S. market, with the company emphasizing a focus on quality and safety protocols. According to Dudum, the initiative will feature a comprehensive experience that goes beyond the medication itself, incorporating clinical-led guidance and ongoing blood testing for users.

Compounded drugs are medications created by pharmacists to meet the specific needs of an individual patient, often when an FDA-approved version is not available or suitable. While the company frames this as a 'best-in-class' development, the move into the compounded drug market is a significant strategic shift for the telehealth platform. The company has not yet provided a specific launch date for these products, but the announcement signals a move toward more personalized, lab-monitored health services. The company’s focus on U.S.-manufactured products is intended to address concerns regarding the supply chain and quality control of compounded substances.